The dual role of empagliflozin: Cardio renal protection in T2DM patients

Shafiq, Aimen; Mahboob, Eman; Samad, Muhammad Ammar; Rehman, Mohammad Hassam Ur; Tharwani, Zoaib Habib

doi:10.1016/j.amsu.2022.104555

Cited by 4 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of chlorine atoms into bioactive compounds, as exemplified by Xarelto 119 , 120 , Jardiance 121 , and Vraylar 122 , among the top 200 marketed small molecule drugs, can significantly alter their bioactivity spectrum and pharmacokinetic properties. The larger atomic radius of chlorine (atomic radius 0.79 Å) compared to hydrogen (atomic radius 0.53 Å) can result in different steric effects 49 , potentially influencing the binding affinity of bioactive compounds.…”

Section: Halogenation Of Bioactive Compoundsmentioning

confidence: 99%

Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

Huo,

Zhao,

Cheng

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Halogenation Of Bioactive Compoundsmentioning

confidence: 99%

Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

Huo,

Zhao,

Cheng

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…During the last decade, sodium-glucose cotransporter inhibitors (SGLT2i), drugs initially developed as insulin independent hypoglycaemic agents, demonstrated useful cardio-and reno-protective properties and became the therapeutic cornerstone in patients having T2DM, especially complicated with CKD and heart failure [175][176][177]; SGLT2i have also been enthusiastically introduced for widespread utilisation as a standard-of-care treatment for patients without T2DM [178]. Some studies concluded that canaglifozin and dapaglifozin decreased the risk of fracture, whereas empaglifozin and ertuglifozin may increase the fracture risk [171].…”

Section: Prognostic Value Of Ckd and Related Factors For Predictingmentioning

confidence: 99%

“…Some studies concluded that canaglifozin and dapaglifozin decreased the risk of fracture, whereas empaglifozin and ertuglifozin may increase the fracture risk [171]. Te mechanism of the latter outcome, which increased over time medication used, was explained by negative efects on bone metabolism (rises of both serum phosphate and PTH levels, decreases in 1,25-dihydroxyvitamin D levels) [176,[179][180][181]. Other studies, however, did not confrm a SGLT2i-fracture association [182,183]; the question whether these agents should be prescribed or withheld in individuals at high risk for OP/OFs requires careful consideration of the risk/beneft balance.…”

Section: Prognostic Value Of Ckd and Related Factors For Predictingmentioning

confidence: 99%

Chronic Kidney Disease in Patients with Hip Fracture: Prevalence and Outcomes

Fisher,

Wang,

Smith

2024

International Journal of Clinical Practice

View full text Add to dashboard Cite

Objective. Although the association between chronic kidney disease (CKD) and osteoporotic fractures is well established, data on CKD combined with hip fracture (HF) are scarce and controversial. We aimed to assess in patients with HF the prevalence of CKD, its impact on hospital mortality and length of stay (LOS) and to determine the prognostic value of CKD to predict hospital outcomes. Methods. Prospectively collected clinical data were analysed in 3623 consecutive HF patients aged ≥65 years (mean age 83.4 ± 7.50 [standard deviation] years; 74.4% females). Results. CKD among older patients with HF is highly prevalent (39.9%), has different clinical characteristics, a 2.5-fold higher mortality rate, and 40% greater risk of prolonged LOS. The strongest risk for a poor outcome was advanced age (>80 years). The risk of death substantially increases in combination with chronic disorders, especially coronary artery disease, anaemia, hyperparathyroidism, and atrial fibrillation; models based only on three variables—CKD stage, age >80, and presence of a specific chronic condition—predicted in-hospital death with good discrimination capability (AUC ≥ 0.700) and reasonable accuracy, the number needed to predict ranged between 5.7 and 14.5. Only 12% of HF patients received osteoporotic drugs prefracture. Conclusion. In HF patients with CKD, the risk of adverse outcomes largely increases in parallel with worsening kidney function and, especially, in combination with comorbidities; models based on three admission variables predict a fatal outcome. Assessment of renal function is essential to preventing osteoporotic fractures.

show abstract

“…Many studies aimed at developing glucose-lowering drugs in patients with type 2 diabetes (T2D) have been published during the last three decades. [1][2][3][4] However, most pharmaceutical glucose-lowering drugs approved for clinical use do not lead to satisfactory treatment. The safety of such drugs is a major drawback.…”

Section: Introductionmentioning

confidence: 99%

Lowering fasting blood glucose with non‐dialyzable material of cranberry extract is dependent on host genetic background, sex and diet

Amer-Sarsour

Tarabeih

Ofek

et al. 2022

Anim Models and Exp Med

View full text Add to dashboard Cite

Background: Type 2 diabetes (T2D) is a polygenic metabolic disease, characterized by high fasting blood glucose (FBG). The ability of cranberry (CRN) fruit to regulate glycemia in T2D patients is well known. Here, a cohort of 13 lines of the genetically diverse Collaborative Cross (CC) mouse model was assessed for the effect of non-dialyzable material (NDM) of cranberry extract in lowering fasting blood glucose.Methods: Eight-week-old mice were maintained on either a standard chow diet (control group) or a high-fat diet (HFD) for 12 weeks, followed by injections of intraperitoneal (IP) NDM (50 mg/kg) per mouse, three times a week for the next 6 weeks.Absolute FBG (mg/dl) was measured bi-weekly and percentage changes in FBG (%FBG) between weeks 0 and 12 were calculated.Results: Statistical analysis showed a significant decrease in FBG between weeks 0 and 12 in male and female mice maintained on CHD. However, a non-significant increase in FBG values was observed in male and female mice maintained on HFD during the same period. Following administration of NDM during the following 6 weeks, the results show a variation in significant levels of FBG lowering between lines, male and female mice and under the different diets. Conclusion:The results suggest that the efficacy of NDM treatment in lowering FGB depends on host genetic background (pharmacogenetics), sex of the mouse (pharmacosex), and diet (pharmacodiet). All these results support the need for follow-up research to better understand and implement a personalized medicine approach/utilization of NDM for reducing FBG. K E Y W O R D Schow diet (CHD), collaborative cross (CC) mouse model, fasting blood glucose (FBG), high-fat diet (HFD), non-dialyzable material (NDM) of cranberry extract, type 2 diabetes (T2D)

show abstract

The dual role of empagliflozin: Cardio renal protection in T2DM patients

Cited by 4 publications

References 52 publications

Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing

Chronic Kidney Disease in Patients with Hip Fracture: Prevalence and Outcomes

Lowering fasting blood glucose with non‐dialyzable material of cranberry extract is dependent on host genetic background, sex and diet

Contact Info

Product

Resources

About